{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T11:45:53Z","timestamp":1767008753589,"version":"3.41.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Mycosis fungoides is the most common subtype of cutaneous T-cell lymphoma, in which the expression of cluster of differentiation 30 (CD30)<jats:sup>+<\/jats:sup> subtype can now be treated with the CD30 antibody conjugate brentuximab vedotin. Diagnostic methods are based on immunohistochemical (IHC) staining followed by manual assessment by pathologists, which is always a subjective calculation. QuPath, an open-source software for digital pathology image analysis, satisfies the requirements of objective approaches.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Ten samples from mycosis fungoides patients with CD30 expression at different stages were stained for CD3 and CD30 by IHC staining, scanned, and quantitative analysis was performed using QuPath (version 2.1). Each slide was independently assessed by 3 board-certified dermatopathologists.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Individual estimates for CD30<jats:sup>+<\/jats:sup>\/CD3<jats:sup>+<\/jats:sup> cells varied among the individual histopathologists (mean coefficient of variation, 0.46; range, 0\u20130.78). QuPath analysis showed excellent separation between the positively stained cells for CD3 and CD30 IHC and other cells and tissue structures, although the results correlated strongly with the respective mean estimates of the 3 histopathologists (Pearson-R 0.93).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The results show a high interobserver variability evaluation of IHC markers, although quantitative image analysis offer a significant advantage for comparison. This is not only relevant for clinical routine but also especially critical in therapeutic studies addressing targeted molecules.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dad.0000000000002330","type":"journal-article","created":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T04:42:32Z","timestamp":1674276152000},"page":"93-98","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["QuPath Analysis for CD30+ Cutaneous T-Cell Lymphoma"],"prefix":"10.1097","volume":"45","author":[{"given":"Cassandra","family":"Cieslak","sequence":"first","affiliation":[{"name":"University Clinic for Dermatology, Johannes Wesling Medical Centre, Minden, Germany;"},{"name":"University Hospital of Ruhr-University, Bochum, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Mitteldorf","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology, University Medical Center G\u00f6ttingen, G\u00f6ttingen, Germany; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanja","family":"Kr\u00f6mer-Olbrisch","sequence":"additional","affiliation":[{"name":"University Clinic for Dermatology, Johannes Wesling Medical Centre, Minden, Germany;"},{"name":"University Hospital of Ruhr-University, Bochum, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werner","family":"Kempf","sequence":"additional","affiliation":[{"name":"Kempf und Pfaltz Histologische Diagnostik, Zurich, Switzerland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2683-6028","authenticated-orcid":false,"given":"Rudolf","family":"Stadler","sequence":"additional","affiliation":[{"name":"University Clinic for Dermatology, Johannes Wesling Medical Centre, Minden, Germany;"},{"name":"University Hospital of Ruhr-University, Bochum, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250616","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1097\/DAD.0000000000000908","article-title":"Primary cutaneous small cell variant of anaplastic large cell lymphoma: a case series and review of the literature","volume":"39","author":"Magro","year":"2017","journal-title":"Am J Dermatopathol."},{"key":"R2-20250616","doi-asserted-by":"crossref","first-page":"9699","DOI":"10.1073\/pnas.93.18.9699","article-title":"CD30\/TNF receptor-associated factor interaction: NF-kappa B activation and binding specificity","volume":"93","author":"Lee","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R3-20250616","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/2040620712443076","article-title":"Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma","volume":"3","author":"Vaklavas","year":"2012","journal-title":"Ther Adv Hematol."},{"key":"R4-20250616","doi-asserted-by":"crossref","first-page":"6428","DOI":"10.1158\/1078-0432.CCR-11-0488","article-title":"Brentuximab vedotin (SGN-35)","volume":"17","author":"Katz","year":"2011","journal-title":"Clin Cancer Res."},{"key":"R5-20250616","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.clml.2012.01.012","article-title":"Clinical binding properties, internalization kinetics, and clinicopathologic activity of brentuximab vedotin: an antibody-drug conjugate for CD30-positive lymphoid neoplasms","volume":"12","author":"Fromm","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"R6-20250616","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","article-title":"cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity","volume":"102","author":"Francisco","year":"2003","journal-title":"Blood"},{"key":"R7-20250616","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1182\/bloodadvances.2021004710","article-title":"Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data","volume":"5","author":"Horwitz","year":"2021","journal-title":"Blood Adv."},{"key":"R8-20250616","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ejca.2021.01.054","article-title":"Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: an ALCANZA sub-analysis","volume":"148","author":"Kim","year":"2021","journal-title":"Eur J Cancer"},{"key":"R9-20250616","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","article-title":"Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and s\u00e9zary syndrome with variable CD30 expression level: a multi-institution collaborative project","volume":"33","author":"Kim","year":"2015","journal-title":"J Clin Oncol."},{"key":"R10-20250616","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/bjd.18535","article-title":"Brentuximab a novel antibody therapy: real-world use confirms efficacy and tolerability for CD30-positive cutaneous lymphoma","volume":"182","author":"Engelina","year":"2020","journal-title":"Br J Dermatol."},{"key":"R11-20250616","first-page":"514","article-title":"Long term survival, time to next treatment and CD30 expression in patients with advanced CD30+ cutaneous T-cell lymphoma treated with Brentuximab vedotin - a monocentric retrospective analysis of twelve patients","volume":"20","author":"Gosmann","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"key":"R12-20250616","article-title":"Brentuximab vedotin in the treatment of cutaneous t-cell lymphomas: data from the Spanish Primary Cutaneous Lymphoma Registry","author":"Muniesa","year":"2022","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"R13-20250616","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2011-05-351346","article-title":"EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma","volume":"118","author":"Kempf","year":"2011","journal-title":"Blood"},{"key":"R14-20250616","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.media.2016.06.037","article-title":"Image analysis and machine learning in digital pathology: challenges and opportunities","volume":"33","author":"Madabhushi","year":"2016","journal-title":"Med Image Anal."},{"key":"R15-20250616","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.csbj.2021.01.022","article-title":"QuPath: the global impact of an open source digital pathology system","volume":"19","author":"Humphries","year":"2021","journal-title":"Comput Struct Biotechnol J."},{"key":"R17-20250616","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/his.13647","article-title":"Interobserver variation in CD30 immunohistochemistry interpretation; consequences for patient selection for targeted treatment","volume":"73","author":"Koens","year":"2018","journal-title":"Histopathology"},{"key":"R18-20250616","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/cup.13894","article-title":"A review of CD30 expression in cutaneous neoplasms","volume":"48","author":"Kampa","year":"2021","journal-title":"J Cutan Pathol."},{"key":"R19-20250616","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/modpathol.2012.235","article-title":"Interobserver variability and the effect of education in the histopathological diagnosis of differentiated vulvar intraepithelial neoplasia","volume":"26","author":"van den Einden","year":"2013","journal-title":"Mod Pathol."},{"key":"R20-20250616","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/s41379-021-00745-6","article-title":"A new tool for technical standardization of the Ki67 immunohistochemical assay","volume":"34","author":"Aung","year":"2021","journal-title":"Mod Pathol."},{"key":"R21-20250616","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41698-017-0022-1","article-title":"Precision histology: how deep learning is poised to revitalize histomorphology for personalized cancer care","volume":"1","author":"Djuric","year":"2017","journal-title":"NPJ Precis Oncol."},{"key":"R22-20250616","doi-asserted-by":"crossref","first-page":"26286","DOI":"10.1038\/srep26286","article-title":"Deep learning as a tool for increased accuracy and efficiency of histopathological diagnosis","volume":"6","author":"Litjens","year":"2016","journal-title":"Sci Rep."},{"key":"R23-20250616","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/his.13516","article-title":"Validation of the systematic scoring of immunohistochemically stained tumour tissue microarrays using QuPath digital image analysis","volume":"73","author":"Loughrey","year":"2018","journal-title":"Histopathology"},{"key":"R24-20250616","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1136\/amiajnl-2012-001540","article-title":"Pathology imaging informatics for quantitative analysis of whole-slide images","volume":"20","author":"Kothari","year":"2013","journal-title":"J Am Med Inform Assoc."}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000002330","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T18:04:28Z","timestamp":1750097068000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000002330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000002330","relation":{},"ISSN":["0193-1091"],"issn-type":[{"type":"print","value":"0193-1091"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"2022-07-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}